Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar:52:100905.
doi: 10.1016/j.blre.2021.100905. Epub 2021 Nov 3.

A review of FLT3 inhibitors in acute myeloid leukemia

Jennifer C Zhao  1 , Sonal Agarwal  1 , Hiba Ahmad  1 , Kejal Amin  1 , Jan Philipp Bewersdorf  2 , Amer M Zeidan  3
Affiliations
Review

A review of FLT3 inhibitors in acute myeloid leukemia

Jennifer C Zhao et al. Blood Rev. 2022 Mar.

Abstract

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia (AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their prognostic implications, multiple FLT3-targeted molecules have been evaluated. Midostaurin is approved in the U.S. and Europe for newly diagnosed FLT3 mutated AML in combination with standard induction and consolidation chemotherapy based on data from the RATIFY study. Gilteritinib is approved for relapsed or refractory FLT3 mutated AML as monotherapy based on the ADMIRAL study. Although significant progress has been made in the treatment of AML with FLT3-targeting, many challenges remain. Several drug resistance mechanisms have been identified, including clonal selection, stromal protection, FLT3-associated mutations, and off-target mutations. The benefit of FLT3 inhibitor maintenance therapy, either post-chemotherapy or post-transplant, remains controversial, although several studies are ongoing.

Keywords: Acute myeloid leukemia; Crenolanib; FLT3; Gilteritinib; Midostaurin; Quizartinib.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
the FLT3 tyrosine kinase comprimses of five domains: extracellular receptor tyrosine kinase (RTK), juxtamembrane domain, tyrosine kinase domain (TKD), kinase insertion domain, and a C-terminus intracellular domain. Internal tandum duplication (ITD) mutation is located in the juxtamembrane domain and causes a gain-of-function of the RTK. Deletions or mutations in the TKD results in a loss of auto-inhibition. The most common TKD mutation involving residue D835 is located in the activation loop of the TKD and may lead to lower binding affinity of type II inhibitors. Mutation involving the “gate-keeper” residue F691 is also located within TKD and may lead to resistance to both type I and II inhibitors. Both ITD and TKD mutations lead to constitutive activation of downstream proliferative signaling cascades. Type I inhibitors bind to both the active and inactive conformation of FLT3 at the ATP binding site, while type II inhibitors bind to a site adjacent to the ATP binding site in the inactive conformation only.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074. - PMC - PubMed
    1. Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Science. 2020;111(2):312–322. - PMC - PubMed
    1. Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105(6):1507–1516. - PMC - PubMed
    1. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909–1918. - PubMed
    1. Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 1994;368:643–648. - PubMed

Publication types

MeSH terms